EFFECT OF SYSTEMIC DISEASES ON THE SIDE EFFECT PROFILES OF ANTICHOLINERGICS IN OVERACTIVE BLADDER PATIENTS

Hypothesis / aims of study
Dry mouth is a common side effect of anticholinergics in overactive bladder (OAB) patients. In OAB patients with systemic diseases, dry mouth could be more prominent than non-systemic disease patients. We evaluated if systemic diseases affect dry mouth before and after anticholinergics in OAB patients.

Study design, materials and methods
Between Jun 2012 and Dec 2012, 104 OAB patients were enrolled in this study. Seventy (67.3%) patients had systemic diseases (cardiovascular, hepatobiliary, immunologic et al., group I) and 34 (32.7%) patients didn’t (group II). Male patients were 40 (38.5%) and female patients were 64 (61.5%). Before and 3 months after anticholinergics treatment, OAB-SS (symptoms score), visual analogue scale (VAS) for dry mouth, body weight and height for BMI (body mass index) were investigated. Clinical parameters of systemic disease group (I) was compared with non-systemic disease group (II) and after age-adjustment comparison was made again. Statistical program was SPSS 12.0 for Windows and statistical methods were independent T-test and ANCOVA. P-values less than 0.05 were regarded as significant.

Results
Age was 64.1±10.2 (range: 43-82) for group I and 56.7±11.6 (range: 38-80) for group II (p=0.001). Symptoms duration was 83.5±68.8 (range: 3-240) months for group I and 49.3±44.7 (range: 3-120) for group II (p=0.003). Baseline VAS scale of group I (15.4±19.7, range: 0-50) was higher than group II (3.3± 6.1, range: 0-20) (p=0.000). After age-adjustment, the difference of baseline VAS scale between 2 groups was still significant (p=0.023). Follow-up VAS scale of group I (33.1±26.4, range: 0-90) was still higher than that of group II (21.9±20.7, range: 0-50) (p=0.035). But, the amount of change of VAS score of group I (17.0± 16.2, range: 0-60) was not different from that of group II (12.7±15.5, range: 0-40) (p=0.233).
BMI of group I (23.8±3.5, range: 16.4-31.6) was higher than group II (22.3±1.9, range: 17.6-26.5) (p=0.007) and after adjustment for BMI, VAS scale of group I was still higher than group II (p=0.002).

Interpretation of results
OAB patients with systemic diseases have higher baseline and after-anticholinergics treatment dry mouth rate than OAB only patients even after adjustment of age and BMI factor. But, the amount of changes of dry mouth severity after anticholinergics were not different between systemic disease group and OAB only group.

Concluding message
As well as well-known age factor, systemic disease itself affects baseline dry mouth and this high baseline xerostomia rate could be the leading cause of significant side effect after anticholinergics in OAB patients with systemic diseases.

Table 1. OAB with systemic diseases have higher baseline and after-treatment dry mouth rate even after age-adjustment.

<table>
<thead>
<tr>
<th>Age(years)</th>
<th>OAB with diseases(n=70)</th>
<th>OAB only(n=34)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Symptom duration(months)</td>
<td>64.1±10.2</td>
<td>56.7±11.6</td>
<td>0.001</td>
</tr>
<tr>
<td>BMI(kg/m²)</td>
<td>83.5±68.8</td>
<td>49.3±44.7</td>
<td>0.003</td>
</tr>
<tr>
<td>VAS score</td>
<td>23.8±3.5</td>
<td>22.3±1.9</td>
<td>0.007</td>
</tr>
<tr>
<td>Baseline</td>
<td>15.4±19.7</td>
<td>3.3±6.1</td>
<td>0.000</td>
</tr>
<tr>
<td>Follow-up</td>
<td>33.1±26.4</td>
<td>21.9±20.7</td>
<td>0.035</td>
</tr>
<tr>
<td>Amount of changes</td>
<td>17.0±16.2</td>
<td>12.7±15.5</td>
<td>0.233</td>
</tr>
</tbody>
</table>

OAB: Overactive Bladder, BMI: Body Mass Index, VAS: Visual Analogue Scale

References

Disclosures
Funding: Astellas Clinical Trial: Yes Public Registry: No RCT: No Subjects: HUMAN Ethics Committee: Inje University, Ilsanpaik Hospital, Institutional Review of Board Helsinki: Yes Informed Consent: Yes